Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESOC 2026 | The management of incidental post-ischemic lesions found on neuroimaging scans

Thomas Meinel, MD, PhD, Bern University Hospital, and University of Bern, Bern, Switzerland, discusses the management of incidental post-ischemic lesions found on neuroimaging scans. Dr Meinel highlights the current uncertainty surrounding therapeutic care for these patients, and describes the development of a referral pathway to provide individualized counseling on preventive measures. This interview took place at the 12th European Stroke Organisation Conference (ESOC) in Maastricht, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

This talk was about what to do if somebody in your clinic on a scan incidentally shows a post-ischemic lesion. This happens extremely often. So, about 10% of all acquired neuroimaging shows these post-ischemic lesions. And if you go back to the patient, he wouldn’t report any symptoms of stroke or TIA in the past. And currently, it’s unclear how to handle this. We know that there is a massive prognostic impact...

This talk was about what to do if somebody in your clinic on a scan incidentally shows a post-ischemic lesion. This happens extremely often. So, about 10% of all acquired neuroimaging shows these post-ischemic lesions. And if you go back to the patient, he wouldn’t report any symptoms of stroke or TIA in the past. And currently, it’s unclear how to handle this. We know that there is a massive prognostic impact. So, patients do have double the risk for manifest stroke and also an increased risk of dementia during follow-up. But all the therapeutic care that we do for manifest stroke is untested in this population, so we don’t know whether to start antithrombotics or what the targets for blood pressure or lipids should be. We don’t know whether we should screen for atrial fibrillation, so I mean, from pathophysiology, all of that seems reasonable. But currently, most clinics actually worldwide ignore the fact, and what we built and implemented is a referral pathway where such patients are identified and then referred to a dedicated outpatient clinic, and then counseled individually on what the best preventive measures for these patients would be.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Disclosures

Speaker fees: Boehringer Ingelheim; Consulting fees: Medtronic, Perospheretech; Research contracts: Boehringer Ingelheim (provision of study drug / compensation of study drug for the DO-IT trial), Swiss National Science Foundation, Swiss Heart Foundation, Horten Health Foundation, Bangerter Rhyner Foundation, Baasch Medicus Foundation, DFG, CIHR, PHRC, British & Dutch Heart Foundations; Clinical trial steering committee: ELAPSE, DO-IT, PASSION; Other: Industry sponsorships for the ESO Stroke Master programme and ESO Stroke Winter School.